A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 1,200 (planned)
- Started
- Nov 26, 2025
- Main results expected
- Nov 1, 2028
- Fully finished
- Dec 1, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Squamous NSCLC Part: Confirmed Objective Response Rate (cORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1
Measured over: Up to 26 months
Squamous and Nonsquamous NSCLC Part: Overall Survival (OS)
Measured over: Up to 26 months
SRI Part: Percentage of Participants with Dose-limiting Toxicities (DLTs)
Measured over: Up to 28 days after first dose (Day 1)
SRI Part: Percentage of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Immune-Related Adverse Events (irAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation and Deaths
Measured over: From screening up to 26 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07217301 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC